Literature DB >> 10362899

Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis.

O Ciccarelli1, E Giugni, A Paolillo, C Mainero, C Gasperini, S Bastianello, C Pozzilli.   

Abstract

The aim of the study was to monitor the natural history of new enhancing lesions in multiple sclerosis (MS) by means of serial gadolinium-enhanced magnetic resonance imaging (MRI). Out of the 63 new enhancing lesions seen on the baseline scan, belonging to 26 relapsing-remitting MS patients, 26 (40%), nine (14%) and four (6%) lesions showed persisting enhancement at first, second and third follow-up scan, respectively. At the end of 5 months of follow-up, 58 (92%) of the new enhancing lesions were detected as T2 hyperintensities, 24 (38%) as T1 hypointensities ('black holes'), and five lesions (8%) disappeared in both T2 and T1 weighted images. Duration of gadolinium enhancement of at least two consecutive scans significantly influenced the development of 'black holes'. No significant correlation was observed between volume, location, configuration of enhancement at baseline and final outcome of the lesion. In individual cases, different evolution of new enhancing lesions was observed at the same time. In conclusion, this study documented that different outcomes of new lesions are unrelated either to the individual patient or to the baseline MRI characteristics. However, prolonged blood-brain-barrier disruption as shown by persisting enhancement significantly influences the lesion outcome. Copyright 1999 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10362899     DOI: 10.1046/j.1468-1331.1999.640455.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  14 in total

Review 1.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

2.  Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis.

Authors:  Z Campbell; D Sahm; K Donohue; J Jamison; M Davis; C Pellicano; S Auh; J Ohayon; J A Frank; N Richert; F Bagnato
Journal:  Neurology       Date:  2012-04-25       Impact factor: 9.910

3.  Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

Authors:  Stuart D Cook; Suhayl Dhib-Jalbut; Peter Dowling; Luca Durelli; Corey Ford; Gavin Giovannoni; June Halper; Colleen Harris; Joseph Herbert; David Li; John A Lincoln; Robert Lisak; Fred D Lublin; Claudia F Lucchinetti; Wayne Moore; Robert T Naismith; Carlos Oehninger; Jack Simon; Maria Pia Sormani
Journal:  Int J MS Care       Date:  2012

4.  Neuroradiological evaluation of demyelinating disease.

Authors:  Jan-Mendelt Tillema; Istvan Pirko
Journal:  Ther Adv Neurol Disord       Date:  2013-07       Impact factor: 6.570

5.  NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.

Authors:  C Alcalá; L Cubas; S Carratalá; F Gascón; C Quintanilla-Bordás; S Gil-Perotín; D Gorriz; F Pérez-Miralles; R Gasque; J Castillo; B Casanova
Journal:  J Neurol       Date:  2022-01-17       Impact factor: 4.849

6.  The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis.

Authors:  Deeya Gaindh; Neal Jeffries; Joan Ohayon; Nancy D Richert; Clelia Pellicano; Joseph A Frank; Henry McFarland; Francesca Bagnato
Journal:  Expert Opin Biol Ther       Date:  2008-12       Impact factor: 4.388

7.  Tissue-specific imaging is a robust methodology to differentiate in vivo T1 black holes with advanced multiple sclerosis-induced damage.

Authors:  M Riva; V N Ikonomidou; J J Ostuni; P van Gelderen; S Auh; J M Ohayon; F Tovar-Moll; N D Richert; J H Duyn; F Bagnato
Journal:  AJNR Am J Neuroradiol       Date:  2009-04-30       Impact factor: 3.825

8.  Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents.

Authors:  Pierluigi Russo; Alessandro Capone; Andrea Paolillo; Francesco Macchia; Federica Ranzato; Gianfranco Costantino; Luca Degli sposti; Luciano Caprino
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

9.  The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis.

Authors:  Rose Gelineau-Morel; Valentina Tomassini; Mark Jenkinson; Heidi Johansen-Berg; Paul M Matthews; Jacqueline Palace
Journal:  Hum Brain Mapp       Date:  2011-10-05       Impact factor: 5.038

10.  Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis.

Authors:  Ilona Lipp; Derek K Jones; Sonya Bells; Eleonora Sgarlata; Catherine Foster; Rachael Stickland; Alison E Davidson; Emma C Tallantyre; Neil P Robertson; Richard G Wise; Valentina Tomassini
Journal:  Hum Brain Mapp       Date:  2019-03-19       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.